IXC Charting Thread

At the request of a few posters who want to start afresh, welcome to the IXC charting thread going forward!

If you're a poster who is inclined to track TA, please feel free to post a chart once a week here and keep us updated.

One Rule: Any more than 1 chart per week per user (particularly 3-4 times a day as we have previously seen in these forums) is not permitted in this thread as it is unnecessary in following illiquid biotech's this far out from Phase III read out and creates unnecessary noise that buries discourse of substance.

Other than that, go wild!

Timeline Annotations of the IXC Chart Story Thus Far
- IXC IPO'd in mid 2019 with Phase II data due Mid 2020, stock performs very well on IPO with tight T20
- The stock rose in anticipation for the Mid 2020 Phase II data read out in early 2020
- Before crashing alongside the Covid 19 Market Crash Hysteria in March 2020
- It quickly rerated into a Positive Phase II Data Readout in April/May 2020
- $26M was raised at $1.30, with Andrew Twiggy Forrest Investing as a cornerstone investor in June 2020
- Initial FDA advice required different primary endpoints than the EMA for EU/UK/AU markets, investors sell due to uncertainty in late 2020
- IXC management decide to pursue the CUV strategy, a company that had a similar situation occur, Mid 2021
- Phase III strategy targets EU/UK/AU markets through an EMA only trial as its the least risk approach for a $1B TAM Market
- Phase III data will then be used for US FDA negotiations for approval or a smaller Phase III trial for a $600M TAM Market
- Stock starts climbing leading into Phase III start in early Jan 2022
- Ukraine War hits, coinciding with interest rate raises globally in March of 2022
- Indexes wipe out -25-30% (S&P500 and Nasdaq, with growth assets with catalysts far out rerating lower) IXC slides alongside
- Phase III is launched with CUV strategy with first patient recruited in late November 2023, to no movement in SP
- Rates continue to rise, stock market continues to deepen, Retail sentiment at all time low, resulting in a sell off to Covid 19 Lows
- Fundamentals have never been better in any other spot on this chart than today, yet sentiment has us sitting at 45c
- Company has $25M and MC is $31M down here, for an EV of $6M
- Company is advertising a CMO position which may indicate the early workstreams of a long talked about Secondary Indication